Cassou-Mounat Thibaut, Balogova Sona, Nataf Valérie, Calzada Marie, Huchet Virginie, Kerrou Khaldoun, Devaux Jean-Yves, Mohty Mohamad, Talbot Jean-Noël, Garderet Laurent
Department of Nuclear Medicine, Hôpital Tenon, AP-HP, 4 rue de la Chine, Paris, 75020, France.
Department of Nuclear Medicine, Hôpital Saint Antoine, AP-HP, 184 rue du Fg St Antoine, Paris, 75012, France.
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1995-2004. doi: 10.1007/s00259-016-3392-7. Epub 2016 Apr 28.
Hybrid positron emission tomography/computed tomography (PET/CT) has now become available, as well as whole-body, low-dose multidetector row computed tomography (MDCT) or magnetic resonance imaging (MRI). The radioactive glucose analogue 18F-fluorodeoxyglucose (FDG) is the most widely used tracer but has a relatively low sensitivity in detecting multiple myeloma (MM). We compared FDG with a more recent metabolic tracer, 18F-fluorocholine (FCH), for the detection of MM lesions at time of disease relapse or progression.
We analyzed the results of FDG and FCH imaging in 21 MM patients undergoing PET/CT for suspected relapsing or progressive MM. For each patient and each tracer, an on-site reader and a masked reader independently determined the number of intraosseous and extraosseous foci of tracer and the intensity of uptake as measured by their SUVmax and the corresponding target/non-target ratio (T/NT).
In the skeleton of 21 patients, no foci were found for two cases, uncountable foci were observed in four patients, including some mismatched FCH/FDG foci. In the 15 patients with countable bone foci, the on-site reader detected 72 FDG foci vs. 127 FCH foci (+76 %), whereas the masked reader detected 69 FDG foci vs. 121 FCH foci (+75 %), both differences being significant. Interobserver agreement on the total number of bone foci was very high, with a kappa coefficient of 0.81 for FDG and 0.89 for FCH. Measurement of uptake in the matched foci that took up both tracers revealed a significantly higher median SUVmax and T/NT for FCH vs. FDG. Almost all unmatched foci were FCH-positive FDG-negative (57/59 = 97 % on-site and 56/60 = 93 % on masked reading); they were more frequently observed than matched foci in the head and neck region.
These findings suggest that PET/CT performed for suspected relapsing or progressive MM would reveal more lesions when using FCH rather than FDG.
如今,正电子发射断层扫描/计算机断层扫描(PET/CT)以及全身低剂量多层螺旋计算机断层扫描(MDCT)或磁共振成像(MRI)均已可用。放射性葡萄糖类似物18F-氟脱氧葡萄糖(FDG)是应用最广泛的示踪剂,但在检测多发性骨髓瘤(MM)方面灵敏度相对较低。我们比较了FDG与一种更新的代谢示踪剂18F-氟胆碱(FCH)在疾病复发或进展时检测MM病灶的情况。
我们分析了21例疑似MM复发或进展而接受PET/CT检查的MM患者的FDG和FCH成像结果。对于每位患者和每种示踪剂,一名现场阅片者和一名盲法阅片者分别独立确定骨内和骨外示踪剂病灶的数量,以及通过其最大标准化摄取值(SUVmax)和相应的靶/非靶比值(T/NT)测量的摄取强度。
在21例患者的骨骼中,2例未发现病灶,4例观察到无法计数的病灶,包括一些FCH/FDG不匹配的病灶。在15例有可计数骨病灶的患者中,现场阅片者检测到72个FDG病灶,而FCH病灶为127个(增加76%);盲法阅片者检测到69个FDG病灶,而FCH病灶为121个(增加75%),两者差异均有统计学意义。观察者间对骨病灶总数的一致性非常高,FDG的kappa系数为0.81,FCH的kappa系数为0.89。对两种示踪剂均摄取的匹配病灶摄取情况的测量显示,FCH的SUVmax和T/NT中位数显著高于FDG。几乎所有不匹配的病灶都是FCH阳性而FDG阴性(现场阅片为57/59 = 97%,盲法阅片为56/60 = 93%);在头颈部区域,不匹配病灶比匹配病灶更常见。
这些发现表明,对于疑似MM复发或进展的患者进行PET/CT检查时,使用FCH比使用FDG能发现更多病灶。